Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
In the latest session, Arbutus Biopharma Corp (NASDAQ: ABUS) closed at $4.47 up 3.71% from its previous closing price of $4.31. In other words, the price has increased by $3.71 from its previous closing price. On the day, 1.07 million shares were traded. ABUS stock price reached its highest trading level at $4.49 during the session, while it also had its lowest trading level at $4.33.
Ratios:
For a deeper understanding of Arbutus Biopharma Corp’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.56 and its Current Ratio is at 6.56. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 14 ’24 when MANCHESTER KEITH S sold 8,846 shares for $3.69 per share. The transaction valued at 32,637 led to the insider holds 46,069 shares of the business.
Sims Karen sold 4,358 shares of ABUS for $10,078 on Feb 02 ’24. The Chief Medical Officer now owns 125,542 shares after completing the transaction at $2.31 per share. On Feb 02 ’24, another insider, HASTINGS DAVID C, who serves as the Chief Financial Officer of the company, sold 9,593 shares for $2.31 each. As a result, the insider received 22,184 and left with 181,907 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABUS now has a Market Capitalization of 843855488 and an Enterprise Value of 709325696. For the stock, the TTM Price-to-Sale (P/S) ratio is 83.88 while its Price-to-Book (P/B) ratio in mrq is 6.89. Its current Enterprise Value per Revenue stands at 70.503 whereas that against EBITDA is -8.758.
Stock Price History:
Over the past 52 weeks, ABUS has reached a high of $4.72, while it has fallen to a 52-week low of $1.69. The 50-Day Moving Average of the stock is 17.31%, while the 200-Day Moving Average is calculated to be 50.11%.
Shares Statistics:
For the past three months, ABUS has traded an average of 1.06M shares per day and 1808860 over the past ten days. A total of 169.87M shares are outstanding, with a floating share count of 146.67M. Insiders hold about 22.31% of the company’s shares, while institutions hold 51.17% stake in the company. Shares short for ABUS as of 1724976000 were 6064382 with a Short Ratio of 5.74, compared to 1722384000 on 6798270. Therefore, it implies a Short% of Shares Outstanding of 6064382 and a Short% of Float of 4.0799997999999995.
